Table 3.
Selected phase III clinical trials on role of maintenance therapy in multiple myeloma.
| Study | Patient population | Maintenance treatment | Median progression-free survival (months) |
|---|---|---|---|
| CALBG 10010475,76 | TE-NDMM | R* | 57.3 |
| IFM 2005-0277 | TE-NDMM | R* | 41 |
| Myeloma XI78 | TE-NDMM | R* | 57 |
| FIRST79 | TIE-NDMM | Rd vs Rd18 | 25.5 vs 20 |
| SWOG S077780 | TIE-NDMM | Rd (VRd induction) | 43 |
| MAIA70 | TIE-NDMM | Rd (DRd induction) | NR |
*Post ASCT.
Abbreviations: TE-NDMM, transplant eligible newly diagnosed multiple myeloma; TIE-NDMM, transplant ineligible newly diagnoses multiple myeloma; R, lenalidomide; Rd, lenalidomide anddexamethasone; VRd, bortezomib lenalidomide and dexamethasone; DRd, daratumumab lenalidomide and dexamethasone; NR, not reached.